BioSpace News Archive

Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, today announced positive interim results from the ALIGN3D™ clinical study in a podium presentation at the ongoing American College of Foot and Ankle Surgeons (ACFAS) Annual Scientific Conference

Health Canada authorized a submission from Pfizer-BioNTech to allow its COVID-19 vaccine to be stored at regular refrigerated temperatures at the point of use for up to one month.

Beckman Coulter, a global clinical diagnostics leader, announced the launch of Access SARS-CoV-2 IgG, a fully-quantitative lab-based Immunoglobulin G serology test that measures the quantity of antibodies against the virus that causes COVID-19.

Ziopharm Oncology, Inc., held its annual shareholders meeting and reinforced its plan and vision for the Company developed and endorsed by the Board and management team.

Critical Path Institute announced the appointment of Robert M. Califf, MD, MACC, head of Clinical Policy and Strategy for Google parent company Alphabet’s Verily Life Sciences and Google Health divisions, to C-Path’s Board of Directors.

Lack of reproducibility is a critical problem in biomedical science, wasting both time and billions of dollars every year.

Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies & applied materials industries, will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021.

Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines, announced that Ryan Spencer, Chief Executive Officer, will participate in a virtual fireside chat at the William Blair 41th Annual Growth Stock Conference on Tuesday, June 1, 2021 at 2:40 p.m. C.T.

Once-daily (QD) dose escalation completed; pharmacokinetic (PK) profile consistent with design principles and preclinical predictions

Sensei Biotherapeutics, a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, announced new data from the ongoing Phase 1/2 clinical trial of SNS-301, an investigational medicine in patients with advanced squamous cell carcinoma of the head and neck, in combination with pembrolizumab.